Development of a prediction model for recurrence in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
© 2024 Published by Elsevier Ltd..
INTRODUCTION: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival outcomes for selected patients with colorectal peritoneal metastases (PM), but recurrence rates are high. The aim of this study was to develop a tool to predict recurrence in patients with colorectal PM that undergo CRS-HIPEC.
MATERIALS AND METHODS: For this retrospective cohort study, data of patients that underwent CRS-HIPEC for colorectal PM from four Dutch HIPEC centers were used. Exclusion criteria were perioperative systemic therapy and peritoneal cancer index (PCI) ≥20. Nine previously identified factors were considered as predictors: gender, age, primary tumor characteristics (location, nodal stage, differentiation, and mutation status), synchronous liver metastases, preoperative Carcino-Embryonal Antigen (CEA), and peritoneal cancer index (PCI). The prediction model was developed using multivariable Cox regression and validated internally using bootstrapping. The performance of the model was evaluated by discrimination and calibration.
RESULTS: In total, 408 patients were included. During the follow-up, recurrence of disease occurred in 318 patients (78%). Significant predictors of recurrence were PCI (HR 1.075, 95% CI 1.044-1.108) and primary tumor location (left sided HR 0.719, 95% CI 0.550-0.939). The prediction model for recurrence showed fair discrimination with a C-index of 0.64 (95% CI 0.62, 0.66) after internal validation. The model was well-calibrated with good agreement between the predicted and observed probabilities.
CONCLUSION: We developed a prediction tool that could aid in the prediction of recurrence in patients with colorectal PM who undergo CRS-HIPEC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - 50(2024), 6 vom: 04. Apr., Seite 108294 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dietz, Michelle V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Colorectal carcinoma |
|---|
| Anmerkungen: |
Date Revised 07.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.ejso.2024.108294 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370726235 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370726235 | ||
| 003 | DE-627 | ||
| 005 | 20240408233301.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240408s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejso.2024.108294 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM370726235 | ||
| 035 | |a (NLM)38583215 | ||
| 035 | |a (PII)S0748-7983(24)00346-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dietz, Michelle V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of a prediction model for recurrence in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 07.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 Published by Elsevier Ltd. | ||
| 520 | |a INTRODUCTION: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival outcomes for selected patients with colorectal peritoneal metastases (PM), but recurrence rates are high. The aim of this study was to develop a tool to predict recurrence in patients with colorectal PM that undergo CRS-HIPEC | ||
| 520 | |a MATERIALS AND METHODS: For this retrospective cohort study, data of patients that underwent CRS-HIPEC for colorectal PM from four Dutch HIPEC centers were used. Exclusion criteria were perioperative systemic therapy and peritoneal cancer index (PCI) ≥20. Nine previously identified factors were considered as predictors: gender, age, primary tumor characteristics (location, nodal stage, differentiation, and mutation status), synchronous liver metastases, preoperative Carcino-Embryonal Antigen (CEA), and peritoneal cancer index (PCI). The prediction model was developed using multivariable Cox regression and validated internally using bootstrapping. The performance of the model was evaluated by discrimination and calibration | ||
| 520 | |a RESULTS: In total, 408 patients were included. During the follow-up, recurrence of disease occurred in 318 patients (78%). Significant predictors of recurrence were PCI (HR 1.075, 95% CI 1.044-1.108) and primary tumor location (left sided HR 0.719, 95% CI 0.550-0.939). The prediction model for recurrence showed fair discrimination with a C-index of 0.64 (95% CI 0.62, 0.66) after internal validation. The model was well-calibrated with good agreement between the predicted and observed probabilities | ||
| 520 | |a CONCLUSION: We developed a prediction tool that could aid in the prediction of recurrence in patients with colorectal PM who undergo CRS-HIPEC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Colorectal carcinoma | |
| 650 | 4 | |a Cytoreductive surgery | |
| 650 | 4 | |a Hyperthermic intraperitoneal chemotherapy | |
| 650 | 4 | |a Peritoneal metastases | |
| 650 | 4 | |a Prediction model | |
| 650 | 4 | |a Recurrence | |
| 700 | 1 | |a Hannink, Gerjon |e verfasserin |4 aut | |
| 700 | 1 | |a Said, Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a van der Zant, Femke A |e verfasserin |4 aut | |
| 700 | 1 | |a van de Vlasakker, Vincent C J |e verfasserin |4 aut | |
| 700 | 1 | |a Brandt-Kerkhof, Alexandra R M |e verfasserin |4 aut | |
| 700 | 1 | |a Verhoef, Cornelis |e verfasserin |4 aut | |
| 700 | 1 | |a Bremers, Andreas J A |e verfasserin |4 aut | |
| 700 | 1 | |a de Wilt, Johannes H W |e verfasserin |4 aut | |
| 700 | 1 | |a Hemmer, Patrick H J |e verfasserin |4 aut | |
| 700 | 1 | |a de Hingh, Ignace H J T |e verfasserin |4 aut | |
| 700 | 1 | |a de Reuver, Philip R |e verfasserin |4 aut | |
| 700 | 1 | |a Madsen, Eva V E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology |d 1993 |g 50(2024), 6 vom: 04. Apr., Seite 108294 |w (DE-627)NLM01262862X |x 1532-2157 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2024 |g number:6 |g day:04 |g month:04 |g pages:108294 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejso.2024.108294 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2024 |e 6 |b 04 |c 04 |h 108294 | ||